Responding to Reimbursement Price Cuts and Healthcare Delivery System Reform
First written in FY2016. 13 of 18 entries say "Materialised", first in FY2017-Q1. Latest entry: FY2024.
Japan Medical Dynamic Marketing moved to the "Worse" side of this theme in 2017, 3 years before the typical company in this theme (2020).
The whole theme swung hardest in 2025: 3 of 8 companies on the "Worse" side.
1 other company's latest entry also says "Materialised".
- FY2024MaterialisedAnnual report
「Although Japan was affected by reimbursement price reductions implemented in April 2023 and January 2024, revenue increased to ¥13,004 million, up ¥647 million, or 5.2%, from the previous consolidated fiscal year, as the number of cases won increased.」
The reimbursement price reductions implemented in April 2023 and January 2024 were implemented, and their impact on domestic revenue emerged in the full-year results. - FY2024-Q3MaterialisedAnnual report
「In Japan, despite the impact of the reimbursement price cut implemented in April 2023, the increase in cases acquired resulted in revenue of ¥9,541 million, up ¥560 million, or 6.2%, year on year, after deducting part of selling expenses following the application of the Accounting Standard for Revenue Recognition.」
The impact of the April 2023 reimbursement price reduction emerged in domestic revenue. The company explained that revenue increased as the number of cases grew. - FY2024-Q1MaterialisedAnnual report
「In Japan, despite the impact of the reimbursement price cut implemented in April 2023, the increase in cases acquired resulted in revenue of ¥3,055 million, up ¥121 million, or 4.1%, year on year, after deducting part of selling expenses following the application of the Accounting Standard for Revenue Recognition.」
The April 2023 reimbursement price reduction was implemented, and its impact emerged in domestic revenue. The company explained that revenue increased as the number of cases won grew. An institutional change anticipated as a business risk materialized in the results. - FY2023-Q3MaterialisedAnnual report
「In Japan, revenue per case declined due to the reimbursement price cut in April 2022, but the number of cases acquired increased year on year, resulting in revenue of ¥8,980 million, up ¥242 million, or 2.8%, year on year.」
The April 2022 reimbursement price reduction was implemented, and its impact emerged in the quarterly results as a decline in revenue per case. - FY2023-Q2MaterialisedAnnual report
「In Japan, reimbursement price cuts caused revenue per case to decline, but the number of cases acquired increased from the same quarter of the previous year, resulting in revenue of ¥5,805 million, up ¥339 million, or 6.2%, year on year.」
A domestic reimbursement price reduction was implemented, and its impact emerged in the results as a decline in revenue per case. - FY2023-Q1MaterialisedAnnual report
「The cost of sales ratio was 33.4% (32.0% in the same quarter of the previous year), due in part to the weaker yen and the impact of reimbursement price revisions in Japan.」
The impact of domestic reimbursement price revisions emerged in the results as a factor behind the increase in the cost of sales ratio for the quarter. - FY2020MaterialisedAnnual report
「Although reimbursement prices were reduced in stages in Japan in April 2019, sales in the osteosynthesis materials field were affected by a decline in the number of cases due to the unusually warm winter and the continued failure to resolve the shortage of OM Femoral Nail System III (product name: ASULOCK), and by the end of the fourth quarter the company had begun to be affected by the novel coronavirus disease (hereinafter, “COVID-19”).」
The phased reimbursement price reduction implemented in April 2019 was confirmed in the results, and the company described a severe environment in which a negative revision was also expected in the 2020 medical fee revision. - FY2020-Q3RestatedAnnual report
「Although reimbursement prices were reduced in stages in Japan in April 2019, revenue increased 10.2% year on year to ¥8,057 million, driven by steady sales in the artificial joint, osteosynthesis materials and spinal fixation device fields.」
The company reiterated that a phased reimbursement price reduction was implemented in April 2019 and that domestic revenue increased despite its impact. - FY2020-Q1MaterialisedAnnual report
「Although reimbursement prices were reduced in stages in Japan in April of the current year, revenue increased 13.0% year on year to ¥2,608 million, driven by steady sales in the artificial joint, osteosynthesis materials and spinal fixation device fields.」
The company stated that a phased reimbursement price reduction was implemented in April of the current year, with institutional risk newly materializing in the results. - FY2019-Q3RestatedAnnual report
「Although reimbursement prices were reduced in Japan in April 2018, revenue increased 6.8% year on year to ¥7,314 million, driven by steady sales in the osteosynthesis materials and spinal fixation device fields.」
The April 2018 reimbursement price reduction and domestic sales trends under its impact were reiterated. This was not a new reduction, but continued confirmation of an institutional change that had already occurred. - FY2019-Q2MaterialisedAnnual report
「Although reimbursement prices were reduced in Japan in April 2018, revenue increased 7.0% year on year to ¥4,587 million, driven by steady sales of products manufactured by the US subsidiary Ortho Development Corporation and other products.」
The company stated that the April 2018 reimbursement price reduction had been implemented and that the impact of the institutional change emerged during the cumulative second-quarter period. - FY2019-Q1MaterialisedAnnual report
「Although reimbursement prices were reduced in Japan in April 2018, revenue increased 6.1% year on year to ¥2,308 million, driven by steady sales of products manufactured by the US subsidiary Ortho Development Corporation and other products.」
The company stated that the April 2018 reimbursement price reduction had been implemented and that the impact of the institutional change emerged in the current quarter. - FY2018-Q1MaterialisedAnnual report
「Although reimbursement prices were reduced in Japan in January and April 2017, revenue increased 2.2% year on year to ¥2,174 million, driven by steady sales of products manufactured by the US subsidiary Ortho Development Corporation (hereinafter, “ODEV”).」
Regarding the reimbursement price reduction reported in the previous fiscal year, the company stated that it was implemented in April following the January 2017 reduction. - FY2017MaterialisedAnnual report
「Although reimbursement prices were reduced in Japan in April 2016 and January 2017, revenue increased 3.8% from the previous fiscal year to ¥9,063 million, driven by steady sales of products manufactured by the US subsidiary Ortho Development Corporation (hereinafter, “ODEV”).」
The full-year results stated that reimbursement prices were reduced in January 2017 in addition to April 2016, meaning that institutional risk materialized on multiple occasions. - FY2017-Q3RestatedAnnual report
「Although reimbursement prices were reduced in Japan in April 2016, revenue increased 4.2% year on year to ¥6,533 million, driven by steady sales of products manufactured by the US subsidiary Ortho Development Corporation (hereinafter, “ODEV”).」
The April 2016 reimbursement price reduction was reiterated, with domestic revenue described as having increased 4.2% year on year despite its impact. - FY2017-Q2RestatedAnnual report
「Although reimbursement prices were reduced in Japan in April 2016, revenue increased 3.6% year on year to ¥6,396 million, driven by steady sales of products manufactured by the US subsidiary Ortho Development Corporation (hereinafter, “ODEV”).」
The April 2016 reimbursement price reduction was reiterated, with sales of products manufactured by the US subsidiary described as remaining steady despite its impact. - FY2017-Q1MaterialisedAnnual report
「Although reimbursement prices were reduced in Japan in April 2016, revenue increased 7.0% year on year to ¥2,126 million, driven by steady sales of products manufactured by the US subsidiary Ortho Development Corporation (hereinafter, “ODEV”).」
The company stated that the reimbursement price reduction anticipated in the previous fiscal year was implemented in April 2016. - FY2016First statedAnnual report
「Various measures are being discussed and implemented, centered on the functional differentiation of medical institutions and the establishment of a comprehensive community-based healthcare and nursing-care system focused on home care. We believe the peak of this transformation will come in 2018. In addition, 2018 will be the year of simultaneous revisions to medical and nursing-care reimbursement. Given the severe condition of the national finances, substantial reimbursement price reductions are also expected, making further cost reductions through company-wide efforts necessary.」
The company has already described the severe business environment resulting from reimbursement price reductions and anticipates institutional reforms, simultaneous revisions and additional reductions in 2018.